#1
#1 out of 1100.00%
health3h ago
New pancreatic cancer pill could reshape treatment as early trial results stun researchers
- Recent early-stage trial shows daraxonrasib achieving disease control in about 90% of metastatic pancreatic cancer patients with RAS mutations.
- Around 30% of participants at the 300-milligram dose showed a positive tumor response in the trial.
- The study was not randomized, so it cannot prove that daraxonrasib is better than standard chemotherapy.
- Lead investigator Dr. Brian Wolpin cautioned that larger trials are needed to confirm efficacy and safety.
- The trial enrolled 168 patients with RAS-mutant metastatic pancreatic cancer who had prior chemotherapy.
- Wolpin described daraxonrasib as a potential shift in pancreatic cancer care pending further validation.
- Common side effects included rash, mouth inflammation, nausea, and diarrhea, but most patients tolerated treatment with supportive care.
- The drug targets multiple cancer signals linked to the RAS gene, potentially addressing a broad set of pancreatic cancers.
- Experts say further research is needed to determine optimal sequencing or combination therapies.
- The findings were published in The New England Journal of Medicine and presented by the Dana-Farber Cancer Institute researchers.
Vote 0